CARTER-WALLACE
ANNUAL REPORT FOR THE YEAR ENDED MARCH 31 2000
EXECUTIVE OFFICES
1345 Avenue of the Americas, New York, N.Y. 10105
212-339-5000
RESEARCH LABORATORIES
Cranbury, New Jersey
MANUFACTURING PLANTS
Cranbury, New Jersey
Colonial Heights, Virginia
Decatur, Illinois
Santa Ana, California
Winsted, Connecticut
Montreal, Canada
Folkestone, England
Milan, Italy
Mexico City, Mexico
New Plymouth, New Zealand
Barcelona, Spain
TRANSFER AND DISBURSING AGENT
The Bank of New York
101 Barclay Street
New York, N.Y. 10286
800-524-4458
REGISTRAR OF STOCK
The Bank of New York
101 Barclay Street
New York, N.Y. 10286
SHAREHOLDER RELATIONS
Ruder Finn, Inc.
800-984-1777
CARTER-WALLACE, INC.
ANNUAL REPORT
For the year ended March 31, 2000
FINANCIAL HIGHLIGHTS 2000 1999
Net sales $747,668,000 $668,872,000
Earnings before taxes 71,036,000 46,244,000
Net earnings 43,332,000 28,209,000
Earnings per share--basic $ .96 $ .62
Earnings per share--diluted $ .94 $ .62
Dividends 10,809,000 9,931,000
Dividends per share $ .24 $ .22
Average shares outstanding 45,019,000 45,180,000
Number of stockholders of record
Common 1,913 2,108
Class B common 1,142 1,241
[LOGO]
The Company markets
toiletries, pharmaceuticals,
diagnostic specialties,
proprietary drugs and pet products
CONTENTS
Report to Stockholders 2
Summary of Selected Financial Data 7
Management's Discussion and
Analysis of Results of Operations
and Financial Condition 8
Description of Business Segments 11
Consolidated Balance Sheets 12
Consolidated Statements of Earnings, Retained
Earnings and Comprehensive Earnings 14
Consolidated Statements of Cash Flows 15
Notes to Consolidated Financial Statements 16
Independent Auditors' Report 30
Directors and Officers 31
Facilities and Corporate Information 32
REPORT TO STOCKHOLDERS
In the fiscal year ended March 31, 2000, sales increased to an all-time high.
The Company's consolidated sales were $747,668,000 compared to the prior year's
sales of $668,872,000, for a gain of 12%.
The Company's earnings increased by 55% to $.96 per basic share for the fiscal
year ended March 31, 2000 compared to $.62 per basic share in the prior year. On
a diluted basis, the Company earned $.94 per share in the current year compared
to $.62 per share in the prior year.
SALES
Sales in the Company's three business segments were Domestic Consumer Products
$304,253,000, Domestic Health Care $206,158,000 and International $237,257,000.
Domestic Consumer Products were 41%, Domestic Health Care were 27% and
International were 32% of total sales. These sales compare to a year ago of
$283,228,000, $181,157,000 and $204,487,000, respectively. Lower foreign
exchange rates had the effect of decreasing International sales by approximately
$10,400,000.
DIVIDENDS
Dividends of $.24 per share were paid in the fiscal year ended March 31, 2000
compared to $.22 per share in the prior year. The Company has paid dividends for
117 consecutive years.
CARTER PRODUCTS DIVISION
The Division achieved another record in sales revenues for the year through
innovative new product introductions and the further strengthening of several
core franchises. This performance was attained even as the retail industry,
particularly food outlets, continued to consolidate. The Division's key brand
segments remained prominent in the market and several Carter Products are the
preeminent brand in their category.
Factory shipments of Trojan brand condoms reached a record high. Combined market
share for all the Division's condom brands continued to rise to over 68% of
total condom category sales this year. Both Trojan and Naturalamb brands
increased their market position. Leadership advertising, effective promotion,
comprehensive educational programs and innovative line extensions continue to
improve the brand's leading position in this market. Trojan Supra polyurethane
condoms were introduced in July 1999.
Sales volume for the Arrid line of anti-perspirants and deodorants increased
year to year even as competition in this category intensified. The Arrid brand
successfully introduced new fragrances for the solid and aerosol segments and
improved the aerosol product for greater efficacy. Arrid also continued its
successful advertising campaign, focusing on the powerful protection of Arrid in
stressful situations.
The Nair line of hair removal products continues to be the number one brand in
this category and has increased sales volume in the depilatory and wax segments.
Nair 4-minute lotion, the Nair Bikini Kit and Nair Raspberry Razz-ma-tazz lotion
were successfully introduced in the latter part of the year, further expanding
the presence of Nair in the fast growing hair removal category.
Pearl Drops continues to be competitive in the specialty tooth whitening
category. This segment faces pressure from mainstream brands that have
introduced whitening line extensions.
The Division continues to be one of the leading marketers of at-home pregnancy
and ovulation test kits. Sales of both the First Response and Answer pregnancy
and ovulation test kits performed well. On a combined basis First Response and
Answer ovulation test kits are number one in this category.
2
WALLACE LABORATORIES DIVISION
The Wallace Laboratories Division posted strong sales performance from the
continued growth of Astelin Nasal Spray and the introduction of several new
cough/cold prescription products.
Astelin Nasal Spray, the only prescription antihistamine nasal spray on the
market, continued to grow. It is the Division's most promoted product throughout
the year, but the heaviest emphasis is during the spring and fall allergy
seasons.
Two studies evaluating Astelin Nasal Spray in patients with vasomotor
(perennial, nonallergic) rhinitis were completed during fiscal 2000. Both
studies demonstrated that Astelin was effective across all the measured symptoms
of vasomotor rhinitis, and a filing was made to the Food and Drug Administration
(FDA) in November 1999 for this indication. If approved, Astelin Nasal Spray
will be the only antihistamine in the United States with claims for both
allergic and nonallergic rhinitis.
A filing to the FDA for the Astelin pediatric indication was made in June 1999.
In May 2000 the Division received approval from the FDA.
Astelin Nasal Spray is marketed under a joint venture agreement with ASTA Medica
AG. Under this agreement, Carter-Wallace, through the Wallace Laboratories
Division, is responsible for all manufacturing, selling, marketing and
administrative services for Astelin and is compensated by the joint company for
these activities.
The Division's cough/cold product line underwent many changes in fiscal 2000.
This includes the reformulation of Rynatan tablets, which was introduced in May
1999 under an agreement with the Warrick Division of Schering-Plough
Corporation. In addition, the Division introduced the prescription cough/ cold
products Ryna-12 Pediatric Suspension, a twice-a-day liquid antihistamine
decongestant, and Tussi-12 tablets for coughs. These products, along with
Tussi-12 suspension, a twice-a day liquid prescription cough preparation
introduced in December 1998, received major promotional support, primarily
during the cough/cold/flu season. As many of these products are appropriate for
pediatric patients, the Division strengthened its promotional efforts in the
pediatric area during fiscal 2000.
While major promotional emphasis was placed on Astelin Nasal Spray and the
cough/cold products, the Soma family of products also received promotional
support targeted to appropriate physicians throughout the year.
The Division continues to explore line extensions, new pharmaceutical products
and licensing/acquisition opportunities that would broaden or complement
existing product lines, as well as co-promotion agreements.
WAMPOLE LABORATORIES DIVISION
Wampole Laboratories closed out the millennium with the best year in its
history. Sales and earnings both grew substantially year over year as the
Division continued to increase market share in key segments and realize the full
benefit from new products introduced in the prior year.
The key to Wampole's growth is its enzyme immunoassay (EIA) business and, once
again, the Division was successful in placing a record number of automated
instrument platforms that utilize Wampole test kits. EIA products to detect
infectious disease, particularly C. difficile, and autoimmune disease showed
very good growth, aided by a full year of sales for Macra Lp(a), a
cardiovascular risk assessment test and MicroTrak Chlamydia.
Results also benefited from a full year of sales for MicroTrak direct
fluorescence assays and for the Analyst point-of-care chemistry system.
Sales of existing point-of-care products were strong, especially in areas of
pregnancy testing, following the forced withdrawal of a major competitor from
the market. Mono-Plus, a rapid test for infectious mononucleosis performed in
the physician's office, continued to demonstrate sales growth well over that of
the market.
3
One of the more significant drivers of Wampole's growth was its alliance with
Allegiance Healthcare, one of the largest distributors of hospital products in
the country. By partnering with Allegiance, the Division is able to effectively
penetrate many of the managed care buying groups with which Allegiance has
preferred vendor status. This relationship is expected to continue to grow and
to contribute to the Division's future success in a rapidly consolidating
marketplace.
LAMBERT KAY DIVISION
Lambert Kay's broad range of pet products, once sold primarily through
independent pet stores, is now found in all major pet chains and many major mass
market outlets. The recent explosion of the Internet has opened another
opportunity for the Division to provide our customers with the products and
convenience they want. This year, several pet product Internet Webstores debuted
and Lambert Kay products are available on most of them. In addition, Lambert
Kay's own Website brings pet owners detailed information on our full range of
products and is updated regularly to highlight new products and other facts and
useful tips that would be of interest to our customers.
Lassie dog products and Tiny Tiger feline products are the Lambert Kay names
displayed on the shelves of mass market and grocery stores. Lambert Kay's
products fall into seven broad categories: grooming aids, grooming tools,
nutritional supplements, medical products, training aids, chain collars and
leads, and toys for dogs and cats.
The Division continued to introduce new products during the year. Two unique pet
shampoos were brought to market. Spot Secure shampoo can be used in between
applications of the popular new "spot-on" flea and tick products whose
protection generally lasts for several weeks. Mr. Spats' no-rinse cat shampoo
eases the frequently awkward job of washing a cat. Because no water is needed to
activate the cleansing action of the product there is less resistance to the
grooming.
In the nutritional category, Shed Relief, a food supplement that helps control
excess shedding in dogs and cats, and Theralin Tabs, complete vitamin and
mineral supplements for dogs and cats, were introduced. Ten new hardware
products were also offered, including the unique Hair Raiser Shedder dead hair
remover. Four new pin and brush grooming aids, under the Twinco brand name, were
also brought to market. This variety of pin and pin/bristle brushes, are needed
to deal effectively with the wide variety of pet coats.
Color Guard prong training collars and accessories, in distinctive gold colored
steel, were added this year to our current wide selection of metal dog collars
and leads.
INTERNATIONAL DIVISION
The International Division achieved substantial growth during the past year,
attaining record sales and profits. All subsidiary operations including Canada,
Mexico, Australia, England, France, Italy and Spain contributed higher sales
during the fiscal year. The Division benefited from higher unit volumes for
existing products, product introductions and line extensions, selective selling
price increases and the full year impact of several consumer product line
acquisitions. These robust results were partially offset by a strengthening U.S.
dollar, which had the effect of reducing the Division's sales and profit
contribution when restated for U.S. financial reporting.
Consumer products displayed sales gains in a number of product segments and
geographic areas. Our depilatory lines performed extremely well, with
significant sales gains for Nair in Mexico and Canada and for Taky in Spain. A
full line of depilatory products was successfully launched in France under the
Nair trademark. Nair continues to be a leading brand in the Middle East. The
full year impact of the acquisition of the Barbara Gould line of facial
cleansing and skin care products lent strength to our performance in France.
Lineance, a line of anticellulite skin care products, continued to maintain a
dominant mass market share in France. In Spain, the
4
market share for the Division's Eudermin skin care products increased as a
result of product line extensions and expanded distribution. Our Curash line of
baby products in Australia, augmented by several new offerings, also achieved
considerable growth during the fiscal year.
Oral care sales advanced during the year with the full year effect of the
acquisition of Ultrafresh in Australia and New Zealand. Ultrafresh is a leading
brand in the mouthwash segment in these countries. Intense competition from a
number of major international brands continues to affect the whitening
toothpolish category; however Pearl Drops maintained a strong showing in
Australia as well as in England, Germany, Switzerland, Holland and Italy. During
the year, Pearl Drops was successfully established in Poland. Denture adhesive
sales increased in Italy as sales of the Orasiv brand in pharmacies have been
complemented by mass-market sales under the Rigident name. The home pregnancy
and ovulation market segments continue to be characterized by an increasing
number of private label brands and severe price competition; however the
Division has maintained a strong presence for its brands in Australia, Canada,
Italy, England and Mexico.
At the end of fiscal 2000, the Trojan brand of condoms attained the number one
market share in Canada. In just over a year, the brand's market share has grown
from 36% at the end of 1998 to the current 41% share. Our brands of topical
analgesic products, Antiphlogisine Rub A-535 maintained its leading position in
Canada and Dencorub continued to perform well in Australia.
The Division's line of OTC health care and pharmaceutical products maintained
strong positions in a number of foreign markets. In Canada, higher sales were
achieved for Gravol antinauseant, Ovol antiflatulent and Bentasil throat
lozenges. In France, Sterimar, a nasal decongestant, continued to grow and
expand its leading market share. OTC health care sales in Italy were very
strong, led by Cerulisina, a preparation to remove ear wax, NeoEmocicatrol, a
topical coagulant, and Verelait, a lactose-based laxative, a product acquired
during the year.
In Mexico, pharmaceutical sales advanced to record levels due to the Pangavit
line of vitamin supplements, Colfur, an antidiarrheal, and Somalgesic, an
analgesic muscle relaxant.
Professional diagnostic sales in France posted moderate growth from the
introduction of several new products, including tests for assessing lipid
metabolism and for diagnosing early stages of toxoplasmosis. A new confirmatory
test for detecting a broad range of parasitic antigens strengthened our
leadership position in parasitology testing. Our subsidiary in Italy continues
to expand its extensive product lines with new tests in both enzyme and
radioimmunoassay technologies. The introduction of new infectious diseases
screening and confirmatory tests, along with tests for cardiovascular disease
and autoimmunity has helped maintain strong sales in Europe. The Isolator
microbiology system continues to maintain successful niche markets in Europe and
Canada.
RESEARCH & DEVELOPMENT
Expenses for research and development totaled $28,508,000 for the fiscal year
ended March 31, 2000, compared to $25,846,000 in the prior fiscal year.
Research at independent facilities determined that taurolidine induced cell
death in numerous human cancer cells in vitro. These developments prompted the
Company to initiate an R&D program directed at multiple cancer cell lines to
determine if taurolidine has clinically important antineoplastic activity. An
Investigational New Drug Application (IND) was filed with and accepted by the
FDA. A clinical trial in patients with ovarian cancer is in progress. Additional
clinical trials in patients with other malignancies, including leukemia and
brain cancer, are planned for the coming year.
Two multicenter Phase III studies showed that Astelin Nasal Spray is effective
for treating vasomotor (perennial, nonallergic) rhinitis. A Supplemental
5
New Drug Application was submitted to the FDA for use in adults with vasomotor
rhinitis. If approved, Astelin Nasal Spray would be indicated for both allergic
and nonallergic vasomotor rhinitis. Another Supplemental New Drug Application
was submitted for Astelin Nasal Spray's use for children under 12 years old and
FDA approval was received in May, 2000. The Astelin tablet NDA for allergic
rhinitis is pending at the FDA. The Company has not decided whether to seek
final approval for this NDA.
The Felbatol (felbamate) Patient Registry, introduced in 1997, continues to
provide useful patient data. The Registry will help determine if a monitoring
test can be developed that will then allow Felbatol to be used with greater
safety for patients with epilepsy. Over one thousand new patients were enrolled
in the Registry by the end of fiscal 2000.
The Company has an option to license a new chemical entity, fluorofelbamate. In
preclinical studies, this entity has four to ten times the antiseizure
effectiveness demonstrated by felbamate.
FACILITIES
In order to meet expected demand for Trojan condoms, an expansion of our condom
manufacturing facility in Colonial Heights, Virginia was approved in fiscal
1998. The expansion was completed on time in fiscal 2000.
* * *
We appreciate the ongoing trust and confidence of the consumers and
professionals who use our products, and the loyal support of our employees,
shareholders and suppliers. We thank them for their interest and confidence in
Carter-Wallace.
Henry H. Hoyt, Jr.,
Chairman of the Board and
Chief Executive Officer
Ralph Levine
President and
Chief Operating Officer
June 13, 2000
6
Carter-Wallace, Inc. and Subsidiaries
SUMMARY OF SELECTED FINANCIAL DATA
- --------------------------------------------------------------------------------
YEARS ENDED MARCH 31
----------------------------------------------------------------
2000 1999 1998 1997 1996
----------------------------------------------------------------
(IN THOUSANDS, EXCEPT PER SHARE AND EMPLOYEE DATA)
OPERATIONS
Net sales $747,668 $668,872 $662,229 $648,755 $658,940
Earnings before one-time charges in 1996
and taxes 71,036 46,244 44,755 45,349 54,797
Net earnings 43,332 28,209 27,301 26,756 7,550(a)
Earnings per share--basic .96 .62 .59 .58 .16(a)
Earnings per share--diluted .94 .62 .59 .58 .16(a)
Dividends per share .24 .22 .16 .16 .16
Average common shares outstanding 45,019 45,180 46,093 46,389 46,160
FINANCIAL POSITION
Working capital $205,447 $159,549 $145,715 $142,972 $137,083
Net property, plant and equipment 149,410 150,596 150,223 154,844 139,273
Total assets 762,236 721,952 693,613 685,922 718,925
Long-term debt 59,541 64,861 48,887 51,025 55,928
Stockholders' equity 391,038 359,156 349,650 349,154 332,896
OTHER DATA
Capital expenditures $ 18,056 $ 17,271 $ 15,676 $ 31,066 $ 35,228
Book value per share 8.65 7.98 7.70 7.53 7.18
Number of employees 3,320 3,310 3,360 3,460 3,610
(a) Reflects one-time charges against pre-tax earnings of $42,000 ($24,780 after
tax or $.54 per share) related to the closure of the Trenton facility,
restructuring charges and net adjustments to the provision for loss on
Felbatol (felbamate) and the discontinuance of the Organidin (iodinated
glycerol) product line.
------------------------------------------------------
QUARTERLY DATA ON COMMON STOCK
The high and low selling prices of the Company's
common stock, principally traded on the New York Stock
Exchange (symbol CAR), for the two most recent fiscal
years were as follows:
FISCAL YEARS ENDED MARCH 31
---------------------------------------------
2000 1999
-------------------- ---------------------
QUARTER ENDED HIGH LOW HIGH LOW
-------- -------- -------- --------
June 30 $18 1/4 $17 3/16 $18 9/16 $16 13/16
September 30 18 9/16 17 9/16 19 1/2 14 5/8
December 31 18 7/8 17 7/16 19 11/16 14 3/8
March 31 19 9/16 17 7/16 19 5/8 15 1/2
A dividend of $.06 per share was declared in all four
quarters of 2000. A dividend of $.04 per share was
declared in the first quarter of 1999 and $.06 per
share was declared in the second, third and fourth
quarters of 1999.
7
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION
- --------------------------------------------------------------------------------
NET SALES AND EARNINGS
Net earnings were $43,332,000 in the year ended March 31, 2000 compared to net
earnings of $28,209,000 in the prior year. Basic earnings per share were $.96
per share in the current year compared to $.62 per share in the prior year, an
increase of 55%. On a diluted basis, earnings per share were $.94 per share
compared to $.62 per share in the prior year.
Net sales in 2000 were $747,668,000 compared to prior year's sales of
$668,872,000, a gain of 12%.
Sales of Domestic Consumer Products increased by $21,025,000 or 7.4% almost
entirely due to higher unit volume. Selling price increases also had a positive
effect on sales in this segment. Domestic condom sales increased versus the
prior year by 7.4%. Domestic anti-perspirant and deodorant sales increased by
7.2% in comparison to the prior year. Domestic sales of Nair depilatory
increased significantly versus 1999.
Domestic Health Care sales increased $25,001,000 or 13.8% in 2000 due to
increased unit volume as well as higher selling prices. The unit volume increase
was due to the continued growth of Astelin Nasal Spray and the introduction of
several new cough/cold prescription products. Sales of most pharmaceutical
products in the Domestic Health Care segment continue to be adversely affected
by generic competition.
Sales of International products increased $32,770,000 or 16.0% in 2000 due to
higher unit volume and, to a lesser extent, selling price increases. A
significant portion of the unit volume increase related to the acquisition of
the Barbara Gould line of skin care products in France and product
introductions. Lower foreign exchange rates had the effect of decreasing sales
in the current year period by approximately $10,400,000.
Net sales in 1999 were $668,872,000 compared to prior year's sales of
$662,229,000.
Sales of Domestic Consumer Products increased $6,547,000 or 2.4% in 1999 almost
entirely due to higher unit volume. Domestic condom sales increased 10.8% over
the prior year. Domestic anti-perspirant and deodorant sales declined 5.5% in
comparison to the prior year.
Domestic Health Care sales decreased $7,804,000 or 4.1% in 1999 due to reduced
unit volume. However, sales of Astelin Nasal Spray were higher than in the prior
year. Selling price increases had a positive effect on sales in this segment.
Sales of International products increased $7,900,000 or 4.0% in 1999 versus the
prior year due to higher unit volume and selling price increases. A portion of
the unit volume increase related to acquisitions of consumer products in the
United Kingdom and Italy. Lower foreign exchange rates had the effect of
decreasing sales in 1999 by approximately $6,700,000.
Interest income increased in 2000 by $646,000 or 14% from the prior year. In
1999 interest income was higher than 1998 by $813,000. The increase in both
years was due primarily to a higher level of interest bearing investments.
Other income decreased by $3,470,000 versus 1999. In 1999 other income increased
by $8,291,000 versus the prior year. See comments in the Astelin section below.
COSTS AND EXPENSES
Cost of goods sold as a percentage of net sales was 36.5% in 2000, 37.9% in 1999
and 36.4% in 1998. The variations from year to year were due primarily to
changes in product mix. Throughout this period the Company has taken steps to
minimize the effects of higher costs by selective price increases and cost
control and reduction measures.
Advertising, marketing and other selling expenses in 2000 increased $25,805,000
or 9.9% as a result of higher spending principally in the International and
8
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION (CONTINUED)
- --------------------------------------------------------------------------------
Domestic Health Care segments. Spending was higher in the International segment
due in part to promotional support for the recently acquired Barbara Gould
product line and product introductions. Spending was higher in the domestic
Health Care segment partly as a result of costs associated with the
introduction of a reformulated version of an existing product and product
introductions. In 1999, advertising, marketing and other selling expenses
increased from the prior year by $988,000 or 0.4% as a result of higher
spending in the Domestic Health Care and International segments. Spending was
lower in the Domestic Consumer Products segment, primarily media advertising.
Research and development expenses increased in 2000 by $2,662,000 or 10.3% due
mostly to increased spending in the Domestic Health Care segment, including
higher spending for taurolidine. In 1999, research and development expenses
decreased $2,939,000 or 10.2%, primarily as a result of lower spending in the
Domestic Consumer Products segment related to non-recurring prior year employee
termination costs.
In 2000, general and administrative expenses decreased by $1,383,000 or 1.6% due
largely to non-recurring prior year employee termination costs related to
organizational changes. General and administrative expenses increased $2,153,000
or 2.6% in 1999 due largely to the aforementioned organizational changes.
Interest expense increased in 2000 by $122,000 or 2.7%. In 1999, interest
expense increased by $184,000 or 4.3% over the prior year. Both of these
increases related to higher levels of borrowing.
Other expenses increased in 2000 by $4,580,000 or 58.7% due to higher non-cash
charges related to incentive plans, and other miscellaneous expenses. In 1999,
other expenses increased by $1,614,000 or 26.1% due to higher non-cash charges
related to incentive plans and amortization of intangibles.
The consolidated income tax rate in 2000, 1999 and 1998 was 39%.
TAUROLIDINE
Research at independent facilities determined that taurolidine induced cell
death in numerous human cancer cells in vitro. These developments prompted the
Company to initiate an R&D program directed at multiple cancer cell lines to
determine if taurolidine has clinically important antineoplastic activity. An
Investigational New Drug Application (IND) was filed with and accepted by the
FDA. A clinical trial in patients with ovarian cancer is in progress. Additional
clinical trials in patients with other malignancies, including leukemia and
brain cancer, are planned for the coming year.
ASTELIN
In July 1998, the Company entered into a joint venture agreement with ASTA
Medica AG with an effective date of November, 1997. Under the terms of the
agreement the Company is responsible for all manufacturing, selling, marketing
and administrative activities for Astelin and Depen, another product licensed
from ASTA Medica AG, and receives compensation for these activities from the
joint venture. Included in other income is $3,981,000 in 2000, $6,782,000 in
1999 and $645,000 in 1998 related to ASTA Medica's share of joint venture
operations.
FELBATOL (FELBAMATE)
As previously reported, in the years ended March 31, 1995 and 1996 the Company
incurred one-time charges to pre-tax earnings totaling $45,980,000 related to
use restrictions for Felbatol. Depending on future sales levels, additional
inventory write-offs may be required. If for any reason the product at some
future date should no longer be available in the market, the Company will incur
an additional one-time charge, consisting primarily of inventory write-offs and
anticipated returns of product currently in the market, in the range of
$15,000,000 on a pre-tax basis.
9
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION (CONTINUED)
- --------------------------------------------------------------------------------
LIQUIDITY AND CAPITAL RESOURCES
Funds provided from operations and the Company's short-term investments and cash
equivalents are the main source for financing working capital requirements,
additions to property, plant and equipment, the payment of dividends and the
purchases of treasury stock. External borrowings are incurred as needed to
satisfy cash requirements related to seasonal business fluctuations and to
finance major facility expansion programs and major acquisitions.
At March 31, 2000, the Company had available various bank credit lines amounting
to $180,200,000 consisting of $160,000,000 in domestic credit lines and
$20,200,000 in foreign credit lines, of which $1,047,000 of the foreign lines
were utilized at March 31, 2000. The domestic lines are made up of a
$150,000,000 revolving credit facility expiring on October 1, 2000 and
$10,000,000 in an uncommitted credit line.
In fiscal 1999, the Company borrowed approximately $15,200,000 to finance
International acquisitions.
Inventory levels increased in both 2000 and 1999 over the previous years due to
a planned increase in condom inventory as well as new product introductions and
acquisitions.
Under stock repurchase programs approved by the Company's Board of Directors,
the Company purchased 246,000 shares at a cost of $3,885,000 in the year ended
March 31, 1999 and 945,000 shares at a cost of $15,890,000 in the year ended
March 31, 1998.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT FINANCIAL MARKET RISK
A portion of the Company's revenues and earnings are exposed to changes in
foreign exchange rates. Where practical, the Company seeks to relate expected
local currency revenues with local currency costs and local currency assets with
local currency liabilities.
The Company's interest bearing investments and a portion of its debt are subject
to interest rate risk. Changes in interest rates could affect interest income
and expense in future periods. The Company invests on a short-term basis.
There has been no material impact on operations from financial market risk
exposure during the year ended March 31, 2000.
YEAR 2000 COMPLIANCE
The Company successfully implemented a plan addressing Year 2000 technology
compliance for its information technology ("IT") and non-IT systems. The cost of
the entire project was approximately $1,500,000 on a pre-tax basis.
CAPITAL EXPENDITURES
Capital expenditures were $18,056,000 in 2000, $17,271,000 in 1999, and
$15,676,000 in 1998. An expansion of the Company's condom manufacturing facility
in Colonial Heights, Virginia was approved in fiscal 1998. The expansion was
completed on time in fiscal 2000.
10
DESCRIPTION OF BUSINESS SEGMENTS
- --------------------------------------------------------------------------------
The Company is engaged in the manufacture and sale of a diversified line of
products in the Domestic Consumer Products, Domestic Health Care and
International business segments described below:
DOMESTIC CONSUMER PRODUCTS
These products are promoted directly to the consumer by television and other
advertising media and are sold to wholesalers and various retailers. They are
manufactured and sold by our consumer products divisions and some are sold
throughout the rest of the world by various subsidiaries and distributors.
Principal products include:
* Arrid Extra Dry and Arrid XX anti-perspirants and deodorants
* Lady's Choice anti-perspirants and deodorants
* Answer and First Response at-home pregnancy and ovulation test kits; First
Response pregnancy planning kit and urinary tract infection kit
* Carter's laxative
* H-R lubricating jelly
* Nair depilatories, waxes and bleach
* Pearl Drops whitening toothpolish and whitening toothpaste
* Rigident denture adhesive
* Trojan, Class Act, Naturalamb and Supra condoms
* Boundary dog and cat repellants
* Fresh 'n Clean grooming products,
stain and odor remover and puppy housebreaking pads
* Lassie and Tiny Tiger pet product lines
* Linatone food supplement
* Twinco chain collars and leads, slicker brushes and combs
DOMESTIC HEALTH CARE
Health care products are promoted primarily to physicians, pharmacists,
hospitals, laboratories and clinics by a staff of specially trained professional
sales representatives and by advertising in professional journals. These
products are manufactured and sold by our professional products divisions and
some are sold throughout the rest of the world by various subsidiaries and
distributors. Principal products include:
* Astelin Nasal Spray for the treatment of symptoms of seasonal allergic
rhinitis
* Felbatol for the treatment of seizures associated with epilepsy
* Organidin NR family of expectorants/antitussives
* Ryna line of cough/cold products
* Tussi-12 cough/cold product
* Soma brand muscle relaxants
* Butisol sedative hypnotic
* Depen penicillamine for severe rheumatoid arthritis
* Doral sedative hypnotic
* Lufyllin xanthine bronchodilator
* Maltsupex laxative
* Vo-SoL topical antibacterial and antifungal agent
* Analyst physician office chemistry system
* Clearview product line of rapid tests for the determination of pregnancy,
group A streptococcus, chlamydia and C. difficile
* Wampole and other branded enzyme and fluorescent immunoassay tests to detect a
broad range of infectious and autoimmune diseases
* Isostat product line to aid in the detection of micro-organisms in blood
* MicroTrak line of immunoassay products for the detection of sexually
transmitted diseases, primarily chlamydia
* Mono-Test, Mono-Latex and Mono-plus for the detection of mononucleosis
* Stat-Crit portable instrument for use in measuring blood hematocrit levels
--------------------------
INTERNATIONAL
In addition to many of the products listed above, the Company sells the
following products exclusively in certain International markets:
CONSUMER PRODUCTS
* Anne French facial cleansing products
* Barbara Gould facial beauty and cleansing products
* Bi-Solution acne treatment products
* Cerox adhesive tapes and bandages
* Confidelle, Discover and Gravix at-home pregnancy test kits
* Cossack line of men's grooming products
* Curash line of skin care products
* Email Diamant toothpastes
* Eudermin line of skin care and toiletry products
* Femfresh line of feminine hygiene products
* GranVista non-prescription eyeglasses
* Lineance line of anti-cellulite and associated skin care products
* Odontovax line of oral hygiene products
* Orasiv denture adhesive
* Poupina line of skin care and toiletry products
* Taky depilatories and waxes
* Ultrafresh mouthwash and breath freshening products
HEALTH CARE
* Antiphlogistine Rub A-535 and Dencorub topical analgesics
* Atasol analgesic/antipyretic
* Bentasil medicated throat lozenges
* Cerulisina otic solution
* Diovol antacid products
* Gravol antinauseant
* Jordan toothbrushes
* Maltlevol and Pangavit vitamin supplements
* Ovol antiflatulent
* Sterimar nasal decongestant
* Technogenetics line of diagnostic tests for thyroid metabolism,
fertility/pregnancy conditions and other hormonal (endocrine) disorders
11
Carter-Wallace, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
AT MARCH 31, 2000 AND 1999
ASSETS 2000 1999
- --------------------------------------------------------------------------------------------------------
CURRENT ASSETS
Cash and cash equivalents $ 62,638,000 $ 49,382,000
Short-term investments 41,150,000 31,870,000
Accounts receivable-trade, less allowances of
$8,030,000 in 2000 and $7,415,000 in 1999 118,710,000 122,196,000
Other receivables 7,759,000 7,164,000
Inventories
Finished goods 63,684,000 54,019,000
Work in process 13,376,000 10,875,000
Raw materials and supplies 29,208,000 25,714,000
------------ ------------
106,268,000 90,608,000
------------ ------------
Deferred taxes 25,496,000 17,128,000
Prepaid expenses and other current assets 11,997,000 11,242,000
------------ ------------
TOTAL CURRENT ASSETS 374,018,000 329,590,000
------------ ------------
PROPERTY, PLANT AND EQUIPMENT, AT COST
Land 4,803,000 3,880,000
Buildings and improvements 111,616,000 111,625,000
Machinery, equipment and fixtures 184,207,000 178,354,000
Leasehold improvements 23,287,000 22,900,000
------------ ------------
323,913,000 316,759,000
Accumulated depreciation and amortization 174,503,000 166,163,000
------------ ------------
149,410,000 150,596,000
------------ ------------
INTANGIBLE ASSETS
Excess of purchase price of businesses acquired over the
net assets at date of acquisition, less amortization 77,457,000 84,463,000
Patents, trademarks, contracts and formulae, less
amortization 47,227,000 51,926,000
------------ ------------
124,684,000 136,389,000
------------ ------------
DEFERRED TAXES 32,652,000 39,366,000
OTHER ASSETS 81,472,000 66,011,000
------------ ------------
$762,236,000 $721,952,000
============ ============
See accompanying notes to consolidated financial statements.
12
LIABILITIES AND STOCKHOLDERS' EQUITY 2000 1999
- --------------------------------------------------------------------------------------------------------
CURRENT LIABILITIES
Accounts payable $ 46,935,000 $ 44,084,000
Accrued expenses 104,485,000 107,267,000
Notes payable 6,711,000 8,134,000
Taxes on income 10,440,000 10,556,000
------------ ------------
TOTAL CURRENT LIABILITIES 168,571,000 170,041,000
------------ ------------
LONG-TERM LIABILITIES
Long-term debt 59,541,000 64,861,000
Deferred compensation 26,647,000 19,931,000
Accrued postretirement benefit obligation 70,308,000 69,241,000
Other long-term liabilities 46,131,000 38,722,000
------------ ------------
TOTAL LONG-TERM LIABILITIES 202,627,000 192,755,000
------------ ------------
STOCKHOLDERS' EQUITY
Preferred stock, authorized 1,000,000 shares,
without par value; issued--none -- --
Common stock, authorized 80,000,000 shares,
par value $1 per share, one vote per share; issued
34,776,000 shares in 2000 and 34,740,000 shares in 1999 34,776,000 34,740,000
Class B common stock, authorized 13,056,800 shares, par
value $1 per share, ten votes per share; issued 12,429,000
shares in 2000 and 12,465,000 in 1999 12,429,000 12,465,000
Capital in excess of par value 4,231,000 4,483,000
Retained earnings 400,616,000 368,093,000
------------ ------------
452,052,000 419,781,000
Less:
Accumulated other comprehensive loss
Foreign currency translation adjustment 31,385,000 27,785,000
Treasury stock at cost--1,857,900 common and 153,600
Class B common shares in 2000 and 2,069,300 common
and 153,600 Class B common shares in 1999 29,629,000 32,840,000
------------ ------------
TOTAL STOCKHOLDERS' EQUITY 391,038,000 359,156,000
------------ ------------
$762,236,000 $721,952,000
============ ============
See accompanying notes to consolidated financial statements.
13
Carter-Wallace, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF
EARNINGS, RETAINED EARNINGS AND
COMPREHENSIVE EARNINGS
THREE YEARS ENDED MARCH 31, 2000
2000 1999 1998
- -----------------------------------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF EARNINGS
Net sales $747,668,000 $668,872,000 $662,229,000
Interest income 5,328,000 4,682,000 3,869,000
Other income 7,648,000 11,118,000 2,827,000
------------ ------------ ------------
760,644,000 684,672,000 668,925,000
------------ ------------ ------------
Cost and Expenses:
Cost of goods sold 272,841,000 253,447,000 241,189,000
Advertising and promotion 146,998,000 131,684,000 134,478,000
Marketing and other selling 140,530,000 130,039,000 126,257,000
Research and development 28,508,000 25,846,000 28,785,000
General and administrative 83,735,000 85,118,000 82,965,000
Interest 4,614,000 4,492,000 4,308,000
Other 12,382,000 7,802,000 6,188,000
------------ ------------ ------------
689,608,000 638,428,000 624,170,000
------------ ------------ ------------
Earnings before taxes on income 71,036,000 46,244,000 44,755,000
Provision for taxes on income 27,704,000 18,035,000 17,454,000
------------ ------------ ------------
Net earnings $ 43,332,000 $ 28,209,000 $ 27,301,000
============ ============ ============
Earnings per share--basic $ .96 $ .62 $ .59
============ ============ ============
Earnings per share--diluted $ .94 $ .62 $ .59
============ ============ ============
CONSOLIDATED STATEMENTS OF RETAINED EARNINGS
Amount at beginning of year $368,093,000 $349,815,000 $329,906,000
Net earnings 43,332,000 28,209,000 27,301,000
------------ ------------ ------------
411,425,000 378,024,000 357,207,000
Dividends--$.24 per share in 2000, $.22 per share
in 1999 and $.16 per share in 1998 (10,809,000) (9,931,000) (7,392,000)
------------ ------------ ------------
Amount at end of year $400,616,000 $368,093,000 $349,815,000
============ ============ ============
CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS
Net earnings $ 43,332,000 $ 28,209,000 $ 27,301,000
Other comprehensive earnings (loss)
Foreign currency translation adjustment (3,600,000) (2,974,000) (3,846,000)
------------ ------------ ------------
Total comprehensive earnings $ 39,732,000 $ 25,235,000 $ 23,455,000
============ ============ ============
See accompanying notes to consolidated financial statements.
14
CONSOLIDATED STATEMENTS OF
CASH FLOWS
THREE YEARS ENDED MARCH 31, 2000
2000 1999 1998
- -----------------------------------------------------------------------------------------------------------
Net earnings $ 43,332,000 $ 28,209,000 $ 27,301,000
Adjustments to reconcile net earnings to cash flows
provided by operating activities:
Cash payments for one-time charges (1,252,000) (2,318,000) (12,495,000)
Depreciation and amortization 17,470,000 16,372,000 15,746,000
Amortization of patents, trademarks, contracts and
formulae 9,066,000 6,199,000 4,996,000
Amortization of excess of purchase price of
businesses acquired over the net assets at date of
acquisition 4,139,000 4,178,000 3,994,000
Other changes in assets and liabilities:
(Increase) decrease in accounts and other
receivables (2,124,000) 3,602,000 (13,151,000)
(Increase) decrease in inventories (17,380,000) (10,289,000) 5,110,000
(Increase) decrease in prepaid expenses (932,000) (3,647,000) 1,743,000
Increase in accounts payable and accrued expenses 5,578,000 8,795,000 15,131,000
Increase in deferred compensation 6,564,000 2,548,000 1,797,000
(Increase) decrease in deferred taxes (1,654,000) 1,998,000 11,329,000
Other changes (9,303,000) (7,263,000) (10,362,000)
------------ ------------ ------------
Cash flows provided by operating activities 53,504,000 48,384,000 51,139,000
------------ ------------ ------------
Cash flows used in investing activities:
Additions to property, plant and equipment (18,056,000) (17,271,000) (15,676,000)
Payments for international acquisitions, net of cash
received:
Barbara Gould product line in France -- (15,129,000) --
Femfresh product line in the U.K. -- (3,633,000) --
Sanodent S.r.l. in Italy -- -- (3,717,000)
Anne French product line in the U.K. -- -- (1,613,000)
(Increase) in short-term investments (9,189,000) (6,273,000) (7,790,000)
Proceeds from sale of property, plant and equipment 1,042,000 371,000 5,881,000
------------ ------------ ------------
Cash flows used in investing activities (26,203,000) (41,935,000) (22,915,000)
------------ ------------ ------------
Cash flows used in financing activities:
Dividends paid (10,809,000) (9,931,000) (7,392,000)
Increase in borrowings 2,781,000 17,385,000 15,719,000
Payments of debt (5,215,000) (11,569,000) (2,644,000)
Purchase of treasury stock (492,000) (4,381,000) (16,685,000)
------------ ------------ ------------
Cash flows used in financing activities (13,735,000) (8,496,000) (11,002,000)
------------ ------------ ------------
Effect of foreign exchange rate changes on cash
and cash equivalents (310,000) (232,000) (685,000)
------------ ------------ ------------
Increase (decrease) in cash and cash equivalents $ 13,256,000 $ (2,279,000) $ 16,537,000
============ ============ ============
See accompanying notes to consolidated financial statements.
15
Carter-Wallace, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The consolidated financial statements include the accounts of Carter-Wallace,
Inc. and all of its subsidiaries (the "Company"). All significant intercompany
transactions have been eliminated.
Revenue Recognition Policy
Revenue is recognized when products are shipped.
Use of Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and use assumptions
that affect certain reported amounts and disclosures. Actual amounts may differ.
Cash Equivalents and Short-term Investments
Cash equivalents consist of short-term securities with maturities of three
months or less when purchased. Investments with a maturity of greater than three
months but less than one year are classified as short-term investments. The
carrying value of cash equivalents and short-term investments approximated fair
value at March 31, 2000 and 1999.
Inventories
Inventories are valued at the lower of cost or market on the first-in, first-out
(FIFO) method, except for certain domestic inventories which are stated at cost
on the last-in, first-out (LIFO) method.
Property, Plant and Equipment
Depreciation is provided over the estimated useful lives of the assets,
principally using the straight line method. Machinery, equipment and fixtures
are depreciated over a period ranging from five to twenty years. Buildings and
improvements are depreciated over a period ranging from twenty to forty years.
Leasehold improvements are amortized on a straight line basis over the life of
the related asset or the life of the lease, whichever is shorter. Expenditures
for renewals and betterments are capitalized. Upon sale or retirement of assets,
the appropriate asset and related accumulated depreciation accounts are adjusted
and the resultant gain or loss is reflected in earnings. Maintenance and repairs
are charged to expense as incurred.
Intangible Assets
The excess of purchase price of businesses acquired over net assets at date of
acquisition is assessed to the product or group of products which constitute the
business acquired and amortized over no longer than 40 years for amounts
relating to acquisitions subsequent to October 31, 1970. The cost of patents,
formulae and contracts is amortized on a straight line basis over their legal or
contractual lives. The cost of trademarks is being amortized over no longer than
40 years for amounts relating to acquisitions subsequent to October 31, 1970.
Amounts related to intangibles acquired prior to October 31, 1970 are not
material.
The Company's policy in assessing the recoverability of intangible assets is to
compare the carrying value of the intangible asset with the undiscounted cash
flow generated by products related to the intangible asset. In addition, the
Company continually evaluates whether adverse developments indicate that an
intangible asset may be impaired.
Income Taxes
Deferred income taxes are determined using the liability method based on the
estimated future tax effects of differences between the financial statement and
tax bases of assets and liabilities given the provisions of enacted tax laws.
Advertising and Marketing Costs
Advertising, promotion and other marketing costs are charged to earnings in the
period in which they are incurred.
Earnings Per Common Share
Basic earnings per share is based on the average number of common and Class B
common shares outstanding during the year: 45,019,000 in 2000, 45,180,000 in
1999 and 46,093,000 in 1998. In computing diluted earnings per share,
incremental shares issuable upon the assumed exercise of stock options and the
vesting of stock awards have been added to the average shares outstanding.
Incremental shares for purposes of calculating diluted earnings per shares
amounted to 1,033,200 in 2000, 688,500 in 1999 and 441,200 in 1998.
2. INVENTORIES
Inventories computed on the last-in, first-out (LIFO) method comprised 14% and
13% of inventories included in current assets at year end 2000 and 1999,
respectively. If these inventories had been valued on the FIFO inventory method
(which approximates current or replacement cost), total inventories would have
been approximately $9,500,000 and $10,100,000 higher than reported at March 31,
2000 and 1999, respectively. Felbatol inventories of $6,387,000 at March 31,
2000 and $8,275,000 at March 31, 1999, not expected to be sold in the next
fiscal year, are included in Other Assets.
16
3. TAXES ON INCOME
The provision for taxes on income was as follows:
2000 1999 1998
----------- ----------- -----------
Current:
Domestic $21,742,000 $ 8,648,000 $ (563,000)
Foreign 7,673,000 7,305,000 6,606,000
----------- ----------- -----------
29,415,000 15,953,000 6,043,000
----------- ----------- -----------
Deferred:
Domestic (1,378,000) 1,869,000 11,436,000
Foreign (333,000) 213,000 (25,000)
----------- ----------- -----------
(1,711,000) 2,082,000 11,411,000
----------- ----------- -----------
Total $27,704,000 $18,035,000 $17,454,000
=========== =========== ===========
The components of income before taxes were as follows:
Domestic $49,696,000 $27,478,000 $27,367,000
Foreign 21,340,000 18,766,000 17,388,000
----------- ----------- -----------
Total $71,036,000 $46,244,000 $44,755,000
=========== =========== ===========
Deferred income taxes are provided for temporary differences between the
financial statement and tax bases of the Company's assets and liabilities. The
temporary differences gave rise to the following deferred tax assets and
liabilities at March 31:
2000 1999
----------- -----------
Postretirement benefit plans $30,160,000 $29,726,000
Employee benefit plans 13,588,000 11,245,000
Accrued liabilities 15,390,000 16,607,000
Asset valuation accounts 16,517,000 16,458,000
All other 8,417,000 7,698,000
Valuation allowances (3,247,000) (3,247,000)
----------- -----------
Total deferred tax assets 80,825,000 78,487,000
----------- -----------
Depreciation 15,011,000 14,200,000
All other 7,666,000 7,793,000
----------- -----------
Total deferred tax liabilities 22,677,000 21,993,000
----------- -----------
Net deferred tax assets $58,148,000 $56,494,000
----------- -----------
Realization of the Company's deferred tax assets is dependent on generating
sufficient taxable income in future years. Although realization is not assured,
management believes it is more likely than not that all of the deferred tax
assets will be realized, except for the valuation allowance amount. However, the
deferred tax assets could be reduced if estimates of future taxable income are
lowered. A valuation allowance is provided when it is more likely than not that
some portion of the deferred tax assets will not be realized.
17
The effective tax rate of the provision for taxes on income as compared with the
U.S. Federal statutory income tax rate was as follows:
2000 1999 1998
---------------------- ---------------------- -----------------------
% TO % TO % TO
TAX PRE-TAX TAX PRE-TAX TAX PRE-TAX
AMOUNT INCOME AMOUNT INCOME AMOUNT INCOME
----------- ----- ----------- ----- ------------ -----
Computed tax expense $24,863,000 35.0% $16,185,000 35.0% $ 15,664,000 35.0%
Foreign income taxed at a
different effective rate 446,000 0.6 1,619,000 3.5 987,000 2.2
State income taxes, net of
federal tax benefit 2,443,000 3.4 1,345,000 2.9 2,082,000 4.7
Amortization of intangibles 534,000 0.8 534,000 1.2 534,000 1.2
Other (582,000) (0.8) (1,648,000) (3.6) (1,813,000) (4.1)
----------- ----- ----------- ----- ------------ -----
Provision for taxes on income $27,704,000 39.0% $18,035,000 39.0% $ 17,454,000 39.0%
=========== ===== =========== ===== ============ =====
The U.S. Internal Revenue Service completed its examination of the Company's tax
returns through fiscal year 1995 resulting in no material impact on the Company.
4. FOREIGN OPERATIONS
Net current assets and net sales of the Company's foreign subsidiaries and
branches operating outside of the United States, and the Company's equity in net
assets and net earnings of such operations were:
2000 1999 1998
------------ ------------ ------------
Net current assets $106,331,000 $ 99,535,000 $ 94,378,000
Equity in net assets 151,392,000 140,992,000 132,718,000
Net sales 235,549,000 202,799,000 194,780,000
Net earnings 14,000,000 11,248,000 10,807,000
The equity adjustment from foreign currency translation is comprised of the
following:
YEARS ENDED MARCH 31
----------------------------------
2000 1999
----------- -----------
Opening balance $27,785,000 $24,811,000
Current year 3,600,000 2,974,000
----------- -----------
Ending balance $31,385,000 $27,785,000
=========== ===========
5. NOTES PAYABLE AND LONG-TERM DEBT
Notes Payable
Notes payable consisting of borrowings from banks under available lines of
credit were $1,047,000, $2,752,000 and $3,402,000 and the current portion of
long-term debt was $4,169,000, $3,103,000 and $8,471,000 at March 31, 2000, 1999
and 1998, respectively. In addition, other short-term notes payable in
international operations amounted to $1,495,000, $2,279,000 and $5,981,000 at
March 31, 2000, 1999 and 1998, respectively. Additional data related to the
amount of short-term borrowings is not presented since it is immaterial.
18
The Company has available various bank credit lines amounting to $180,200,000 of
which $160,000,000 is for domestic borrowings and $20,200,000 is for
international borrowings. The availability of the lines of credit is subject to
review by the banks involved. Commitment fees are immaterial.
Long-Term Debt
Long-term debt at March 31 is summarized below:
2000 1999
----------- -----------
Promissory Notes, 7.62%, payable in equal annual installments of
$7,000,000 from December 21, 2003 through December 21, 2007 $35,000,000 $35,000,000
Unsecured Euro term loan, 4.10%, payable in installments beginning June
1, 2002 through March 1, 2004 8,882,000 10,143,000
Unsecured French franc term loan, 4.10%, payable in installments through
February 25, 2006 3,860,000 5,043,000
City of Decatur, Illinois adjustable rate Industrial Revenue Bond,
payable December 1, 2010 3,000,000 3,000,000
Unsecured Italian lira term loan, adjustable rate, payable in
installments through December 31, 2004 2,992,000 3,416,000
Unsecured French franc loan, 5.10%, payable February 24, 2003 2,944,000 3,362,000
Unsecured French franc loan, adjustable rate, payable in installments
through April 1, 2006 2,208,000 --
Secured Italian lira term loans, adjustable rate, payable in
installments through July 1, 2001 1,499,000 2,780,000
Promissory Notes, 5.42%, payable no later than September 12, 2000 1,424,000 1,630,000
Unsecured French franc loan, adjustable rate, payable in installments
through September 18, 2003 1,105,000 1,849,000
Unsecured French franc loan, 4.50%, payable in installments through
August 5, 2001 399,000 1,192,000
Other Long-Term Debt 397,000 549,000
----------- -----------
63,710,000 67,964,000
Less, current portion of long-term debt included in notes payable (4,169,000) (3,103,000)
----------- -----------
$59,541,000 $64,861,000
=========== ===========
Maturities of long-term debt for each of the four fiscal years 2002 through 2005
are $2,604,000, $8,232,000, $13,419,000 and $10,507,000, respectively.
Interest on the City of Decatur, Illinois Industrial Revenue Bond is 70% of the
prime rate through December, 2000, adjustable thereafter.
With respect to the Italian lira loan payable through December 31, 2004,
interest on this loan is the Euro Interbank Offered Rate plus a nominal
increment.
With respect to the French franc loan payable February 24, 2003, interest is
adjustable based on the Paris Interbank Offered Rate plus a nominal increment,
adjusted quarterly and was converted to a fixed rate at the inception of the
loan.
With respect to the French franc loan payable through April 1, 2006, interest on
this loan is the Euro Interbank Offered Rate plus a nominal increment.
19
The Italian lira loans due July 1, 2001 are secured by irrevocable letters of
credit. Commitment fees are immaterial. Interest on these loans is the Milan
Interbank Offered Rate plus a nominal increment, adjusted quarterly.
The Company issued promissory notes, payable no later than September 12, 2000,
in connection with the acquisition of the net assets of Youngs Drug Products
Corporation and affiliates. Prepayments of all or portions of the notes are
required as certain contractual conditions are satisfied.
With respect to the French franc loan payable through September 18, 2003,
interest on this loan is the Euro Interbank Offered Rate plus a nominal
increment.
Certain of the Company's long-term debt agreements contain covenants which
require the Company to maintain a minimum level of net worth and limit total
long-term liabilities to a stated percentage of total capitalization.
The fair value of long-term debt, including current maturities, was $60,366,000
at March 31, 2000 and $70,532,000 at March 31, 1999.
6. COMMON STOCK, CLASS B COMMON STOCK AND CAPITAL IN EXCESS OF PAR VALUE
The Company has two classes of common stock with a par value of $1.00 per share.
Class B common stock generally has ten votes per share on all matters and votes
as a class with common stock which has one vote per share. The transfer of Class
B common stock is restricted; however, Class B common stock is at all times
convertible into shares of common stock on a share-for-share basis. Common stock
and Class B common stock have identical rights with respect to cash dividends
and upon liquidation.
Activity for the years ended March 31, 2000, 1999 and 1998 was as follows:
CLASS B CAPITAL IN
COMMON COMMON EXCESS OF
STOCK STOCK PAR VALUE
----------- ----------- -----------
Balance at March 31, 1997 $34,655,000 $12,550,000 $ 3,588,000
Conversion of Class B common stock to Common Stock 43,000 (43,000) --
Cost of treasury stock under market value at date of
award or issuance -- -- 616,000
----------- ----------- -----------
Balance at March 31, 1998 34,698,000 12,507,000 4,204,000
Conversion of Class B common stock to Common Stock 42,000 (42,000) --
Cost of treasury stock under market value at date of
award or issuance -- -- 279,000
----------- ----------- -----------
Balance at March 31, 1999 34,740,000 12,465,000 4,483,000
Conversion of Class B common stock to Common Stock 36,000 (36,000) --
Cost of treasury stock over market value at date of award
or issuance -- -- (252,000)
----------- ----------- -----------
Balance at March 31, 2000 $34,776,000 $12,429,000 $ 4,231,000
=========== =========== ===========
The cost of treasury stock over or under the market value of the stock on the
date of the award or issuance has been applied to capital in excess of par
value, as well as any tax benefit on the appreciation of restricted stock
awards.
Shares issued from treasury stock for stock awards amounted to 239,100, 28,000
and 36,400 shares at a cost of $3,703,000, $429,000 and $502,000 in 2000, 1999
and 1998, respectively. Shares purchased and added to treasury stock amounted to
27,700, 274,400 and 993,000 shares at a cost of $492,000, $4,381,000 and
$16,685,000 in 2000, 1999 and 1998, respectively. In 1999, the Company exchanged
155,500 shares with a value of $2,125,000 previously issued as restricted stock
awards for an equivalent number of deferred stock awards.
7. RETIREMENT PLANS AND OTHER POSTRETIREMENT BENEFITS (DOLLARS IN THOUSANDS)
The Company has several contributory and non-contributory pension plans in which
substantially all employees with over one year of service participate. The
Company's funding policy is to make annual contributions to these plans in
amounts equal to the minimum required by applicable regulations. The plans'
assets are invested primarily in common stocks and corporate and government
bonds.
The Company also provides certain health care and insurance benefits for retired
employees. The cost of the benefits is accrued during the years the employees
render service until they attain full eligibility for those benefits.
20
The components of the pension and postretirement benefit expense for the years
ended March 31, 2000, 1999 and 1998 were:
RETIREMENT PLANS OTHER POSTRETIREMENT BENEFITS
------------------------------- -------------------------------
2000 1999 1998 2000 1999 1998
------- ------- ------- ------- ------- -------
Service cost $ 8,819 $ 8,332 $ 7,511 $ 1,946 $ 1,924 $ 1,689
Interest cost 15,455 14,846 14,785 3,734 3,775 3,871
Expected return on assets (22,000) (20,179) (18,743) -- -- --
Amortization of prior service cost 2,358 2,270 2,253 (1,037) (3,415) (3,452)
Amortization of transition cost (2,074) (2,065) (2,086) -- -- --
Amortization of actuarial (gain) (23) (153) (10) (465) (328) (308)
Settlement losses -- -- 728 -- -- --
------- ------- ------- ------- ------- -------
Total benefit expense $ 2,535 $ 3,051 $ 4,438 $ 4,178 $ 1,956 $ 1,800
======= ======= ======= ======= ======= =======
The components of the changes in the benefit obligation were as follows:
OTHER POSTRETIREMENT
RETIREMENT PLANS BENEFITS
----------------------- -----------------------
2000 1999 2000 1999
-------- -------- -------- --------
Benefit obligation at beginning of year $229,885 $213,311 $ 57,776 $ 55,344
Service cost 8,819 8,332 1,946 1,924
Interest cost 15,455 14,846 3,734 3,775
Plan participants' contributions 367 331 -- --
Amendments 20,196 849 -- --
Actuarial (gain)/loss (29,207) 10,255 (9,649) (1,369)
Effect of exchange rate changes 737 (1,138) 54 (78)
Benefits paid (15,512) (16,901) (3,229) (1,820)
-------- -------- -------- --------
Benefit obligation at end of year $230,740 $229,885 $ 50,632 $ 57,776
======== ======== ======== ========
The components of the changes in plan assets were as follows:
Fair value of plan assets at beginning of year $263,568 $241,454 -- --
Actual return on plan assets 36,754 36,859 -- --
Employer contributions 1,212 2,257 $ 3,229 $ 1,820
Plan participants' contributions 367 331 -- --
Effect of exchange rate changes 802 (432) -- --
Benefits paid (15,512) (16,901) (3,229) (1,820)
-------- -------- -------- --------
Fair value of plan assets at end of year $287,191 $263,568 -- --
======== ======== ======== ========
The following is a reconciliation of the funded status of the plans to the
Company's balance sheets at March 31:
Funded status $ 56,451 $ 33,683 $(50,632) $(57,776)
Unrecognized actuarial (gain) (87,187) (43,255) (18,905) (9,805)
Unrecognized prior service cost 28,202 10,353 (771) (1,660)
Unrecognized transition amounts 265 (1,801) -- --
Minimum liability adjustment (3,206) (5,509) -- --
-------- -------- -------- --------
Accrued benefit cost $ (5,475) $ (6,529) $(70,308) $(69,241)
======== ======== ======== ========
Amounts recognized in the Company's balance sheets at March 31 were as follows:
Other assets $ 29,533 $ 24,745 -- --
Accrued expenses (12,582) (14,093) -- --
Long-term liabilities (22,426) (17,181) $(70,308) $(69,241)
Intangible assets 3,206 5,509 -- --
-------- -------- -------- --------
Net amount recognized $ (2,269) $ (1,020) $(70,308) $(69,241)
======== ======== ======== ========
21
Plan amendments made in fiscal 2000 included a change related to credited
service and a federally mandated actuarial change related to mortality tables.
At March 31, the only pension plans with accumulated benefit obligations in
excess of plan assets were unfunded non-qualified plans which had no assets.
Information on these plans is as follows:
2000 1999
------- -------
Projected Benefit Obligation $45,782 $39,248
======= =======
Accumulated Benefit Obligation $31,568 $28,303
======= =======
The principal assumptions used in determining 2000, 1999 and 1998 actuarial
values were:
Discount rate 6.75 - 8%
Rate of increase in compensation levels 4 - 6%
Expected long-term rate of return on plan assets 8 -10%
Expense for the employee savings plan under which the Company matches the
contributions of participating employees up to a designated level was
$1,514,000, $1,478,000 and $1,473,000 in 2000, 1999 and 1998, respectively.
The assumed health care cost trend rate used to measure the accumulated
postretirement benefit obligation for those over age 65 is 9 percent for 2000
trending to 5 percent over a four year period. For those under age 65, the trend
rate is 6.7 percent for 2000 trending to 5 percent over a four year period. A
one percent increase or decrease in the assumed respective annual medical cost
trend rate would change the accumulated postretirement benefit obligation by
approximately $2,700,000 and the service and interest components of net
postretirement benefit expense by approximately $300,000.
8. LONG-TERM INCENTIVE PLANS
1977 Restricted Stock Award Plan
The plan as amended provides for awards of not more than 2,750,000 shares of
common stock, subject to adjustments for stock splits, stock dividends and other
changes in the Company's capitalization, to key employees, to be issued either
immediately after the award or at a future date. As a result of the
three-for-one stock split in April, 1992 and the issuance of the Class B common
stock in 1987, the 2,750,000 shares of common stock provided for in the Plan
have been adjusted to 5,593,154 shares. As provided in the Plan and subject to
restrictions, shares awarded may not be disposed of by the recipients for a
period of five years from the date of the award. Cash dividends on shares
awarded are held by the Company for the benefit of the recipients, subject to
the same restrictions as the award. Such dividends (without interest) are paid
to the recipients upon lapse of the restrictions. The cost of the awards, equal
to the fair market value at the date of award, is being charged to operations in
equal annual amounts over a five year period commencing at the date of the
award.
Cumulative awards as of March 31, 2000 amount to 3,466,250 shares. There were no
new awards granted in any of the past three fiscal years.
The financial statements reflect the transfer of the awarded shares from
treasury stock as of the date of their issuance. For shares that have been
issued, the market value at the date of the awards was $540,000, $708,000 and
$1,118,000 in 2000, 1999 and 1998, respectively. The cost of treasury stock for
these awards was $428,000, $429,000 and $502,000 in 2000, 1999 and 1998,
respectively.
1996 Long-Term Incentive Plan
The plan as amended provides for awards of not more than 9,000,000 shares of
common stock, subject to adjustment for stock splits, stock dividends and other
changes in the Company's capitalization, to key employees, to be issued either
immediately after the award or at a future date. The awards consist of
restricted and/or deferred stock or options, or a combination thereof. At
March 31, 2000, 5,856,329 shares had been granted under the 1996 long-term
incentive plan.
22
Stock Options
Under the plan, both qualified and non-qualified options may be granted to key
executive employees at fair market value at the date of grant. The right to
exercise the options, in installments, commences one year from the date of grant
and expires ten years after that date. As permitted by Statement of Financial
Accounting Standards ("SFAS") No. 123, "Accounting for Stock-Based
Compensation", the Company has chosen to continue to account for options granted
under the plan using the intrinsic value method. Accordingly, no compensation
expense has been recognized for these options. Had the fair value method of
accounting, as defined in SFAS No. 123, been applied to the Company's stock
options, the Company's net income would have been reduced by approximately
$4,510,000 or $.10 per share in 2000, $3,390,000 or $.08 per share in 1999 and
$1,940,000 or $.04 per share in 1998. The weighted-average fair market value of
options granted was $7.86, $7.71 and $7.31 in 2000, 1999 and 1998, respectively.
For purposes of fair market value disclosures, the fair market value of an
option grant was estimated on the date of grant using the Black-Scholes
option-pricing model with the following weighted-average assumptions:
2000 1999 1998
---- ---- ----
Risk-Free Interest Rate 6.3% 4.9% 5.9%
Expected Life 8 yrs. 8 yrs. 8 yrs.
Volatility 31.7% 35.4% 36.3%
Dividend Yield 1.2% 1.1% 1.3%
A summary of the status of stock options granted under the plan as of March 31,
2000, 1999 and 1998 and changes during the years ended on those dates is
presented below:
2000 1999 1998
-------------------------- -------------------------- --------------------------
WEIGHTED-AVG. WEIGHTED-AVG. WEIGHTED-AVG.
OPTION EXERCISE OPTION EXERCISE OPTION EXERCISE
SHARES PRICE SHARES PRICE SHARES PRICE
--------- ------- --------- ------- --------- -------
Outstanding April 1 3,672,143 $ 15.70 2,479,601 $ 14.70 1,432,220 $ 13.63
Granted 683,926 18.06 1,192,542 17.77 1,047,381 16.16
Exercised -- -- -- -- -- --
Forfeited (52,440) 14.38 -- -- -- --
--------- --------- ---------
Outstanding March 31 4,303,629 $ 16.09 3,672,143 $ 15.70 2,479,601 $ 14.70
========= ========= =========
The following table summarizes information about stock options outstanding at
March 31, 2000:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
--------------------------------------------------- -------------------------------
RANGE OF NUMBER WEIGHTED-AVG. WEIGHTED-AVG. NUMBER WEIGHTED-AVG.
EXERCISE OUTSTANDING REMAINING EXERCISE EXERCISABLE EXERCISE
PRICES AT 3/31/00 LIFE PRICE AT 3/31/00 PRICE
- ------------- --------- --------- ------- --------- -------
$12.13 to
$19.69 4,303,629 7.8 years $ 16.09 2,266,806 $ 15.10
Stock Awards
Restricted and/or deferred stock awards which are awarded subject to
restrictions, may not be disposed of by the recipient for a period of four years
from the date of the award. Cash dividends on shares awarded are held by the
Company for the benefit of the recipients, subject to the same restrictions as
the award. Such dividends (without interest) are paid to the recipients upon
lapse of the restrictions. The cost of the awards, equal to the fair market
value at the date of award, is being charged to operations in equal annual
amounts over the four-year vesting period commencing at the date of the award.
Amortization related to stock awards made under the 1996 Long Term Incentive
Plan amounted to $5,729,000, $2,860,000 and $1,498,000 in 2000, 1999 and 1998,
respectively. If a recipient's employment terminates by reason of retirement,
death or permanent disability, the award would vest immediately with the
unamortized value of the award charged to operations at that time.
Award transactions for the past three years were:
SHARES
---------------------------------------------
2000 1999 1998
--------- ------- -------
Cumulative Awards--Beginning of
Year 909,053 606,689 361,168
New Awards 648,834 302,364 245,521
Forfeited Awards (5,187) -- --
--------- ------- -------
Cumulative Awards--End of Year 1,552,700 909,053 606,689
========= ======= =======
23
The financial statements reflect the transfer of the awarded shares from
treasury stock as of the date of their issuance. Outstanding awards of 1,323,882
shares at March 31, 2000 will be issued at a future date no later than four
years from the date of the award. For shares that have been issued, the market
value at the date of the awards was $2,911,000 in 2000. The cost of treasury
stock for these awards was $3,275,000 in 2000. The differences between the
market value at the date of the awards and the cost of the treasury stock were
included in capital in excess of par value or retained earnings.
9. ACQUISITIONS
At the beginning of fiscal 1999, the Company acquired the Femfresh line of
feminine hygiene products in England for approximately $3,600,000.
In February, 1999, the Company acquired the Barbara Gould line of skin care
products in France for approximately $15,100,000. Sales of this product line
commenced in the fiscal year beginning April 1, 1999. An additional payment may
be required upon achievement of certain sales objectives.
In December, 1997, the Company acquired Sanodent S.r.l. in Italy for
approximately $3,800,000. Sanodent manufactures and sells denture adhesives
under the Orasiv brand name.
In February, 1998, the Company acquired the Anne French line of skin care
products in England for approximately $1,600,000.
These acquisitions are being accounted for by the purchase method and,
accordingly, their results of operations are included in the Company's results
of operations from the acquisition date. Pro forma results of operations are not
presented since the effect would not be material.
10. SHORT-TERM INVESTMENTS
At March 31, 2000 and 1999, short-term investments were intended to be held to
maturity and have remaining maturities of less than one year. The amortized cost
approximated fair value. The amortized cost of certificates of deposit were
$19,649,000 and $12,977,000, respectively, in 2000 and 1999. The amortized cost
of commercial paper was $21,501,000 and $13,174,000 in 2000 and 1999. In
addition, included in 1999 are Canadian government securities in the amount of
$5,719,000.
11. BUSINESS SEGMENTS (DOLLARS IN THOUSANDS)
The Company's reportable business segments are Domestic Consumer Products,
Domestic Health Care and International. Information on the Company's Business
Segments is presented below.
Domestic Consumer Products primarily include anti-perspirants and deodorants,
condoms, at-home pregnancy and ovulation test kits, hair removal products, tooth
whitening products and various pet products. These products are promoted
directly to the consumer by television and other advertising media and are sold
to wholesalers and various retailers. They are manufactured and sold by the
Company's consumer products divisions.
Domestic Health Care products primarily include prescription pharmaceuticals as
well as professional diagnostic products. These products are promoted to
physicians, pharmacists, hospitals, laboratories and clinics by a staff of
specially trained professional sales representatives and by advertising in
professional journals. These products are manufactured and sold by the Company's
health care products divisions.
International products primarily include consumer products such as
anti-perspirants and deodorants, condoms, at-home pregnancy and ovulation test
kits, skin care and oral hygiene products, as well as health care products such
as over the counter pharmaceuticals and diagnostic products. These products are
sold throughout the world by various subsidiaries and distributors.
International products include many of the same consumer and health care
products which are sold domestically, as well as certain consumer and health
care products which are sold exclusively in international markets.
24
Some of the Company's domestic divisions sell to a small number of high volume
customers, the largest of which accounted for approximately 9.6%, 9.6% and 9.0%
of consolidated net sales in 2000, 1999 and 1998, respectively.
MARCH 31
---------------------------------------------------------
2000 1999 1998
--------- -------- --------
Sales
Domestic Consumer Products $ 304,253 $283,228 $276,681
Domestic Health Care 206,158 181,157 188,961
International 237,257 204,487 196,587
--------- -------- --------
Consolidated $ 747,668 $668,872 $662,229
========= ======== ========
Operating Profit
Domestic Consumer Products $ 58,585 $ 44,807 $ 33,409
Domestic Health Care 48,729 40,282 49,115
International 17,765 14,969 13,664
Domestic net interest expense (1,481) (2,037) (2,044)
Other (expense) net of other income (15,037) (12,091) (7,606)
General Corporate expenses (37,525) (39,686) (41,783)
--------- -------- --------
Earnings before taxes on income $ 71,036 $ 46,244 $ 44,755
========= ======== ========
Identifiable Assets
Domestic Consumer Products $ 219,359 $211,776 $210,011
Domestic Health Care 105,885 119,783 122,784
International 187,230 177,759 154,501
Corporate Assets 249,762 212,634 206,317
--------- -------- --------
Total Assets $ 762,236 $721,952 $693,613
========= ======== ========
Depreciation and Amortization
Domestic Consumer Products $ 11,778 $ 10,805 $ 10,139
Domestic Health Care 6,161 6,187 6,027
International 5,535 5,339 5,195
--------- -------- --------
Total Operating Segments $ 23,474 $ 22,331 $ 21,361
========= ======== ========
Capital Expenditures
Domestic Consumer Products $ 7,984 $ 12,553 $ 8,038
Domestic Health Care 1,246 1,678 4,094
International 8,331 2,838 3,102
--------- -------- --------
Total Operating Segments $ 17,561 $ 17,069 $ 15,234
========= ======== ========
Corporate assets include principally cash and cash equivalents, short-term
investments, miscellaneous receivables, deferred taxes and other miscellaneous
assets.
25
12. RENTAL EXPENSE AND LEASE COMMITMENTS (DOLLARS IN THOUSANDS)
Rental expense for operating leases with a term greater than one year for 2000,
1999 and 1998 was as follows:
REAL PROPERTY
RENTAL REAL SUB-RENTAL NET REAL EQUIPMENT
EXPENSE PROPERTY INCOME PROPERTY AND OTHER
- --------------- -------- ------------- ------------- --------------
2000 $ 8,285 $ (2,929) $ 5,356 $ 6,990
1999 8,021 (2,702) 5,319 6,837
1998 8,056 (2,749) 5,307 6,615
The real property rental expense for 2000, 1999 and 1998 excludes approximately
$1,000, $1,000 and $900, respectively, of rental costs which have been charged
to the one-time charges for restructuring of operations and facilities.
Minimum rental commitments, in thousands of dollars, under non-cancellable
leases in effect at March 31, 2000 were as follows:
REAL PROPERTY
MINIMUM RENTAL REAL SUB-RENTAL NET REAL EQUIPMENT CAPITAL LEASE
COMMITMENTS PROPERTY INCOME PROPERTY AND OTHER OBLIGATIONS
- --------------- -------- ------------- ------------- -------------- -------------
2001 $ 9,748 $ (3,235) $ 6,513 $881 $ 547
2002 9,185 (3,462) 5,723 504 445
2003 8,181 (3,462) 4,719 114 285
2004 7,556 (3,462) 4,094 31 212
2005 7,226 (3,462) 3,764 2 199
2006-2012 48,415 (22,718) 25,697 -- 133
-------
1,821
Less interest and executory cost (261)
-------
Present value of minimum lease payments (of which $506 is included in current
liabilities) $ 1,560
=======
Included in the real property rental commitments indicated above is
approximately $14,600 of future rental costs which were included in the one-time
charges for restructuring of operations and facilities. These costs are
associated with the subleasing of office space on which the Company holds a
long-term lease.
26
13. SUPPLEMENTAL FINANCIAL INFORMATION
The following is presented in support of balance sheet captions:
MARCH 31
--------------------------------
2000 1999
-------- --------
(dollars in thousands)
Intangible Assets:
Excess of purchase price of businesses acquired over the
net assets at date of acquisition $114,738 $121,339
Trademarks 47,889 48,714
Other 28,995 32,525
-------- --------
191,622 202,578
Accumulated amortization 66,938 66,189
-------- --------
$124,684 $136,389
======== ========
Accounts Payable:
Trade $ 45,913 $ 43,388
Other 1,022 696
-------- --------
$ 46,935 $ 44,084
======== ========
Accrued Expenses:
Salaries and wages $ 31,376 $ 32,920
Advertising and promotion 19,233 21,144
One-time charges 1,373 1,476
Retirement and related plans 13,383 15,411
Other 39,120 36,316
-------- --------
$104,485 $107,267
======== ========
Other Long-Term Liabilities:
Retirement plans $ 22,426 $ 17,181
One-time charges 8,700 9,867
Other 15,005 11,674
-------- --------
$ 46,131 $ 38,722
======== ========
Income taxes paid were $29,264,000, $21,959,000 and $6,584,000 in 2000, 1999 and
1998, respectively. Interest paid was $4,422,000, $4,527,000 and $4,047,000 in
2000, 1999 and 1998, respectively.
Included in other income is $3,981,000 in 2000, $6,782,000 in 1999 and $645,000
in 1998 related to ASTA Medica's share of joint venture operations.
14. LITIGATION INCLUDING ENVIRONMENTAL MATTER
Environmental Matter
The Company faces potential liability involving waste material generated by the
Lambert Kay division at its former manufacturing facility in Winsted,
Connecticut. In May 1991, the United States Environmental Protection Agency
("EPA") issued special notice letters under the Comprehensive Environmental
Response, Compensation and Liability Act to Lambert Kay and about 50 other
potentially responsible parties ("PRPs") notifying them of potential liability
with respect to waste deposited at the Barkhamsted-New Hartford landfill in
Barkhamsted, Connecticut. In September 1991 and in February 1994, the Company
and 21 other PRPs, without admitting liability, entered into consent agreements
under which the PRPs agreed to perform certain investigation and engineering
evaluation work at the site, including the remedial investigation and
feasibility study, and to reimburse EPA for certain costs. The estimated cost of
this work is about $4.1 million. The Company's share of this cost is estimated
to be $157,000, which includes an allowance for insolvency or nonpayment of
other PRPs' shares. To date the Company has paid or received credit for about
$140,000. In addition, the Company and other settling PRPs have sued certain
nonsettlors for their share of these costs and have obtained some settlement
recoveries. Based on preliminary information from the site investigation work
(which is not completed), the total cost for performing the current and future
work
27
at Barkhamsted, including the site investigation work, is estimated to be from
$6 to $32 million. In June 1995, the Connecticut legislature authorized the
issuance of bonds to pay for approximately $7 million of the future cleanup
costs at the site. The issuance of these bonds is expected to reduce by that
amount those cleanup costs subject to PRP funding. Based on expected PRP
participation in future cleanup work and other factors, the Company anticipates
that its share of projected cleanup costs subject to PRP funding (including
costs incurred to date) will be not more than 4 to 5% of total cleanup costs,
and that the Company's total expenditure will therefore range from about
$250,000 to $1,500,000. Thus, although applicable environmental law provides for
joint and several liability for the cost of cleanup work, based on present
estimates, the Company believes that the other PRPs will pay substantially all
of their allocated percentage shares of cleanup costs.
The Company believes, based upon the information available at this time, that
the environmental matter discussed above will not have a material effect on its
financial statements.
Litigation
Two federal securities class action suits filed in 1994 by stockholders against
the Company and certain of its present and former officers in the United States
District Court, Southern District of New York, were consolidated for all
purposes. A Consolidated Amended Complaint was filed, followed by a Second
Amended Class Action Complaint. The consolidated action purports to be on behalf
of all persons who purchased the Company stock in the period from January 20,
1994 through July 31, 1994. The complaint alleges that certain statements made
by the Company with respect to the safety and anticipated future sales of its
anti-epilepsy drug Felbatol were false and misleading. Both the Consolidated
Amended Complaint and the Second Amended Class Action Complaint, which seek
damages in an unspecified amount, were dismissed by the District Court for
failure to state a claim upon which relief can be granted. The United States
Court of Appeals for the Second Circuit affirmed the dismissal on all claims
except those based on allegedly false statements in medical journal
advertisements. The Company then moved for judgment on the pleadings with
respect to those remaining claims, and the motion was granted. Plaintiffs'
appeal is pending.
The Company, along with numerous other drug manufacturers, wholesalers and
suppliers, was named in a series of class action suits, the first of which was
filed in August, 1994 in the California Superior Court, San Francisco County.
These suits were brought on behalf of all California independent retail
pharmacists who had purchased any brand name prescription drugs since August,
1989. The complaint alleged that the defendants, including the Company, entered
into a conspiracy to fix prices for brand-name prescription drugs and gave lower
prices to certain favored purchasers, while the alleged favored prices were
denied to the plaintiffs. Plaintiffs are seeking injunctive relief and
unspecified trebled compensatory damages, restitution of unspecified amounts by
which defendants are alleged to be unjustly enriched and litigation costs,
interest and attorney's fees. Class certification of the price-fixing conspiracy
claims was granted by order dated June 23, 1995, establishing a class of
independent retail pharmacists and small chains with ten or fewer California
locations. An individual action brought by two mid-size chain pharmacies was
subsequently coordinated with the consolidated class action as an "add-on" case
asserting virtually identical claims and demands for relief. Plaintiffs in that
action have amended their complaint to seek class certification, which has not
been granted. There has been no activity in these cases since 1996 because of
the pendency of related actions brought under the federal antitrust laws. The
Company believes that the claims against it are materially deficient.
The Company is engaged in litigation with Tambrands Inc. in Supreme Court of the
State and County of New York arising out of a patent infringement and
misappropriation suit previously filed against both companies in the United
States District Court, Southern District of New York, by New Horizons
Diagnostics Corporation ("NHDC"), et al. The NHDC suit, which was settled and
discontinued in July 1996, asserted claims with respect to certain "gold sol"
technology (used in the Company's First Response and Answer home pregnancy and
ovulation predictor test kits) that the Company had acquired from Tambrands
pursuant to a written purchase agreement in March 1990. The Company paid an
immaterial amount toward that settlement. In the pending Supreme Court action,
Tambrands seeks reimbursement from the Company of an unspecified portion of the
amount paid by Tambrands in settlement of the NHDC suit, and for defense costs.
The parties are presently engaged in discovery. The Company believes it has good
defenses, under the terms of the purchase agreement, to Tambrands' claim.
The Company is subject to other legal actions arising out of its operations. The
Company believes, based on the opinion of counsel, that it has good defenses to
such actions and should prevail.
28
15. QUARTERLY FINANCIAL DATA (UNAUDITED)
Quarterly net sales, gross margin, net earnings and earnings per share are set
forth in the following table (dollars in thousands, except per share amounts).
QUARTER ENDED
--------------------------------------------------
2000 JUNE 30 SEPT. 30 DEC. 31 MARCH 31 TOTAL YEAR
Net sales $199,954 $185,147 $192,066 $170,501 $747,668
Gross margin 124,878 116,215 126,313 107,421 474,827
Net earnings 13,161 9,400 13,956 6,815 43,332
Earnings per share--basic .29 .21 .31 .15 .96
Earnings per share--diluted .29 .20 .30 .15 .94
1999
Net sales $169,662 $169,169 $162,241 $167,800 $668,872
Gross margin 106,247 102,402 99,517 107,259 415,425
Net earnings 9,493 5,916 7,839 4,961 28,209
Earnings per share--basic and
diluted .21 .13 .17 .11 .62
16. FELBATOL (FELBAMATE)
As previously reported, in the years ended March 31, 1995 and 1996 the Company
incurred one-time charges to pre-tax earnings totaling $45,980,000 related to
use restrictions for Felbatol. Depending on future sales levels, additional
inventory write-offs may be required. If for any reason the product at some
future date should no longer be available in the market, the Company will incur
an additional one-time charge, consisting primarily of inventory write-offs and
anticipated returns of product currently in the market, in the range of
$15,000,000 on a pre-tax basis.
29
[KPMG LOGO]
345 Park Avenue
New York, NY 10154
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
Carter-Wallace, Inc.:
We have audited the accompanying consolidated balance sheets of Carter-Wallace,
Inc. and subsidiaries as of March 31, 2000 and 1999, and the related
consolidated statements of earnings, retained earnings and comprehensive
earnings, and cash flows, for each of the years in the three-year period ended
March 31, 2000. These consolidated financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on
these consolidated financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Carter-Wallace, Inc.
and subsidiaries as of March 31, 2000 and 1999, and the results of their
operations and their cash flows for each of the years in the three-year period
ended March 31, 2000, in conformity with accounting principles generally
accepted in the United States of America.
May 10, 2000
30
Carter-Wallace, Inc. and Subsidiaries
BOARD OF DIRECTORS
Henry H. Hoyt, Jr.
Chairman and Chief Executive Officer
Ralph Levine
President and Chief Operating Officer
Paul A. Veteri
Executive Vice President and Chief Financial Officer
David M. Baldwin
Chairman, David M. Baldwin Realty Company, Inc.
Dr. Richard L. Cruess
Professor of Surgery, Center for Medical Education,
McGill University
Montreal, Quebec, Canada
Suzanne H. Garcia
Owner, La Tierra Beneficiaries (real estate development)
and Santa Fe Ranch
Scott C. Hoyt
Vice President, New Products
Carter Products Division of the Company
Herbert M. Rinaldi
Of Counsel
Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein
SCIENTIFIC ADVISORY BOARD
Joseph S. Harun, M.D., Chairman
Former Vice President, Medical and Scientific Affairs
Carter-Wallace, Inc.
Paul Calabresi, M.D.
Professor of Medicine and Chairman Emeritus,
Department of Medicine
Brown University
Director, Brown-Tufts Cancer Center
Providence, RI - Boston, MA
Robert E. Canfield, M.D.
Irving Professor of Medicine
Columbia University, College of Physicians and Surgeons
New York, NY
Barton F. Haynes, M.D.
Chairman, Department of Medicine
Duke University Medical Center
Durham, NC
Noel Rose, M.D., Ph.D.
Professor of Pathology, Molecular Microbiology and Immunology
Director of Immunology
Johns Hopkins University, Schools of Medicine and Public Health
Baltimore, MD
Morton K. Schwartz, Ph.D.
Chairman, Department of Clinical Laboratories
Memorial Sloan Kettering Cancer Center
New York, NY
EXECUTIVE OFFICERS
Henry H. Hoyt, Jr.
Chairman of the Board and Chief Executive Officer
Ralph Levine
President and Chief Operating Officer
Paul A. Veteri
Executive Vice President and Chief Financial Officer
T. Rosie Albright
Vice President, Consumer Products, U.S.
John Bridgen, Ph.D.
Vice President, Diagnostics, U.S.
James C. Costin, M.D.
Vice President, Medical and Scientific Affairs
Donald R. Daoust, Ph.D.
Vice President, Quality Control
Thomas G. Gerstmyer
Vice President, Pharmaceuticals, U.S.
Peter J. Griffin
Vice President and Controller
Adrian J. L. Huns
Vice President, International
Michael J. Kopec
Vice President, Manufacturing
Stephen R. Lang
Vice President, Secretary and General Counsel
Thomas B. Moorhead
Vice President, Human Resources
C. Richard Stafford
Vice President, Corporate Development
James L. Wagar
Vice President and Treasurer
Mark Wertlieb
Vice President, Taxes
DIVISIONAL MANAGEMENT
T. Rosie Albright, President, Carter Products
John Bridgen, Ph.D., President, Wampole Laboratories
Thomas G. Gerstmyer, President, Wallace Laboratories
Adrian J. L. Huns, President, International
Michael J. Kopec, President, Manufacturing
Thomas M. McShane, President, Lambert Kay
PRINCIPAL SUBSIDIARIES
Howard E. Cocker, Managing Director, Carter-Wallace Limited (United Kingdom)
Francois Depoil, President, Laboratoires Fumouze S. A. (France)
Gregory J. Drohan, President, Carter-Horner Inc. (Canada)
Alan W. Nash, Managing Director, Carter-Wallace (Australia) Pty. Limited
Jordi Pruja, Managing Director, Icart S.A. (Spain)
Stephen W. Riley, President, Carter Wallace, S. A. (Mexico)
Lino Santambrogio, Managing Director, S.p.A. Italiana
Laboratori Bouty (Italy)
31
32 Printed in U.S.A.
CARTER-WALLACE, INC.
1345 Avenue of the Americas
New York, NY 10105